Why a Topical Cannabidiol Gel May Help Treat the Behavioral Symptoms of Fragile X

Fragile X syndrome is a rare, genetic, developmental disorder that is the leading known cause of both intellectual disability and autism spectrum disorder. People with the condition can have a range of behavioral symptoms, such as social avoidance and irritability. Zynerba is developing its experimental therapy Zygel, a topical cannabidiol gel that is delivered into the bloodstream through the skin to treat the behavioral symptoms of Fragile X. We spoke to co-director of the molecular diagnostics section of the Genetic Laboratory at Rush Medical College Elizabeth Berry-Kravis and Zynerba Chairman and CEO Armando Anido, about Fragile X, the company’s experimental therapy Zygel, and why the topical cannibidiol gel may hold promise for treating the behavioral symptoms of the condition.